Tonix Pharmaceuticals Holding Corp.
About Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $13.1M
- Net income
- -$124.0M
- Total assets
- $277.2M
- Market cap
- $176.5M
- Gross margin
- 49.3%
- Operating margin
- -959.1%
- Net margin
- -946.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $13.1M
- Cost of revenue
- $6.6M
- Gross profit
- $6.5M
- Operating expenses
- $132.2M
- Operating income
- -$125.7M
- Net income
- -$124.0M
- EPS (basic)
- $-14.57
- EPS (diluted)
- $-14.57
Balance sheet
- Total assets
- $277.2M
- Current assets
- $228.9M
- Total liabilities
- $32.0M
- Current liabilities
- $30.8M
- Shareholders’ equity
- $245.2M
Cash flow
- Operating cash flow
- -$99.8M
- Investing cash flow
- -$4.5M
- Financing cash flow
- $214.5M
- Net cash flow
- $110.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $176.5M
- EPS (diluted)
- $-14.57
- Shares outstanding
- 15.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Feb 13, 2009
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $124.0M in FY2025.
- Gross margin of 49.3%, net margin -946.2%.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Tonix Pharmaceuticals Holding Corp..
Write a review
News about Tonix Pharmaceuticals Holding Corp.
News & sentiment via Polygon.io
